Literature DB >> 15147565

Irradiation up-regulates CD80 expression through two different mechanisms in spleen B cells, B lymphoma cells, and dendritic cells.

Hideko Torihata1, Fumio Ishikawa, Yayoi Okada, Yuriko Tanaka, Tetsuya Uchida, Toru Suguro, Terutaka Kakiuchi.   

Abstract

We have previously demonstrated irradiation-induced up-regulation of CD80 expression in A20-HL B lymphoma cells by inducing expression of tumour necrosis factor-alpha (TNF-alpha) and CD154. In the present study, we investigated whether irradiation also up-regulates CD80 expression in mouse spleen B cells. Because freshly prepared spleen B cells are highly sensitive to irradiation, we employed spleen B cells stimulated with lipopolysaccharide (LPS-B cells). X-irradiation (8 Gy) followed by incubation (9-12 hr) highly and selectively up-regulated CD80 expression in LPS-B cells, whereas the same treatment slightly increased expression of CD54 and did not affect expression of CD86, major histocompatibility complex class II, CD11a or surface immunoglobulin M. The irradiation-induced up-regulation of CD80 expression resulted in enhanced APC function of LPS-B cells. Up-regulation of CD80 expression on LPS-B cells was accompanied by an increase in CD80 mRNA accumulation and nuclear factor (NF)-kappaB activation. Activation of NF-kappaB was shown to be critical for up-regulation of CD80 expression as pyrrolidine dithiocarbamate (PDTC), an inhibitor of NF-kappaB, severely decreased the observed up-regulation. X-irradiation of LPS-B cells induced expression of TNF-alpha but not CD154. However, anti-TNF-alpha monoclonal antibody (mAb) with anti-CD154 mAb did not inhibit X-irradiation-induced up-regulation of CD80 expression in LPS-B cells, whereas these mAbs almost completely inhibited this up-regulation in A20-HL cells and bone marrow-derived dendritic cells (DCs). In contrast, a thiol antioxidant, N-acetyl-l-cysteine, completely blocked X-irradiation-induced up-regulation of CD80 expression in LPS-B cells, but not in A20-HL cells or in DCs. Based on these findings, we concluded that X-irradiation up-regulates CD80 expression not only in A20-HL cells and DCs but also in LPS-B cells, and that this up-regulation in LPS-B cells via NF-kappaB activation is dependent on the generation of reactive oxygen species, while that in A20-HL cells and DCs is not.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15147565      PMCID: PMC1782476          DOI: 10.1111/j.1365-2567.2004.01872.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  49 in total

1.  T suppressor lymphocytes inhibit NF-kappa B-mediated transcription of CD86 gene in APC.

Authors:  J Li; Z Liu; S Jiang; R Cortesini; S Lederman; N Suciu-Foca
Journal:  J Immunol       Date:  1999-12-15       Impact factor: 5.422

2.  Irradiation of genetically modified plasmacytoma vaccines results in upregulation of CD80 molecule expression, IL-2 production and higher therapeutic efficacy of the vaccines.

Authors:  J Símová; M Reinis; V Sobota; J Capková; J Bubeník; T Jandlová
Journal:  Folia Biol (Praha)       Date:  2000       Impact factor: 0.906

3.  Tumor necrosis factor-alpha generates reactive oxygen species via a cytosolic phospholipase A2-linked cascade.

Authors:  C H Woo; Y W Eom; M H Yoo; H J You; H J Han; W K Song; Y J Yoo; J S Chun; J H Kim
Journal:  J Biol Chem       Date:  2000-10-13       Impact factor: 5.157

Review 4.  Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy.

Authors:  D L Mueller; M K Jenkins; R H Schwartz
Journal:  Annu Rev Immunol       Date:  1989       Impact factor: 28.527

5.  Differential sensitivity of specific and nonspecific antigen-presentation by B cells to a protein synthesis inhibitor.

Authors:  T Kakiuchi; M Watanabe; N Hozumi; H Nariuchi
Journal:  J Immunol       Date:  1990-09-15       Impact factor: 5.422

6.  Antigen presentation by a B-cell line transfected with cloned immunoglobulin heavy- and light-chain genes specific for a defined hapten.

Authors:  M Watanabe; D R Wegmann; A Ochi; N Hozumi
Journal:  Proc Natl Acad Sci U S A       Date:  1986-07       Impact factor: 11.205

7.  gamma-ray irradiation induces B7.1 expression in myeloid leukaemic cells.

Authors:  R Vereecque; G Buffenoir; R Gonzalez; N Cambier; D Hetuin; F Bauters; P Fenaux; B Quesnel
Journal:  Br J Haematol       Date:  2000-03       Impact factor: 6.998

8.  Enhancement of B7-1 (CD80) expression on B-lymphoma cells by irradiation.

Authors:  A Seo; F Ishikawa; H Nakano; H Nakazaki; K Kobayashi; T Kakiuchi
Journal:  Immunology       Date:  1999-04       Impact factor: 7.397

9.  Melphalan and other anticancer modalities up-regulate B7-1 gene expression in tumor cells.

Authors:  D K Sojka; M Donepudi; J A Bluestone; M B Mokyr
Journal:  J Immunol       Date:  2000-06-15       Impact factor: 5.422

10.  Upregulation of ICAM-1 expression on J774.2 macrophages by endotoxin involves activation of NF-kappaB but not protein tyrosine kinase: comparison to induction of iNOS.

Authors:  H Ruetten; C Thiemermann; M Perretti
Journal:  Mediators Inflamm       Date:  1999       Impact factor: 4.711

View more
  12 in total

Review 1.  Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy.

Authors:  Christopher A Klebanoff; Hung T Khong; Paul A Antony; Douglas C Palmer; Nicholas P Restifo
Journal:  Trends Immunol       Date:  2005-02       Impact factor: 16.687

2.  Inflammatory cells of immunosuppressive phenotypes in oral lichen planus have a proinflammatory pattern of expression and are associated with clinical parameters.

Authors:  Marilena Vered; Eran Fürth; Yifat Shalev; Dan Dayan
Journal:  Clin Oral Investig       Date:  2012-08-15       Impact factor: 3.573

Review 3.  Stereotactic Ablative Radiation Therapy Combined With Immunotherapy for Solid Tumors.

Authors:  Eric D Brooks; Jonathan E Schoenhals; Chad Tang; Goran Micevic; Daniel R Gomez; Joe Y Chang; James W Welsh
Journal:  Cancer J       Date:  2016 Jul-Aug       Impact factor: 3.360

4.  CD8+ T cells targeting a single immunodominant epitope are sufficient for elimination of established SV40 T antigen-induced brain tumors.

Authors:  Angela M Tatum; Lawrence M Mylin; Susan J Bender; Matthew A Fischer; Beth A Vigliotti; M Judith Tevethia; Satvir S Tevethia; Todd D Schell
Journal:  J Immunol       Date:  2008-09-15       Impact factor: 5.422

Review 5.  Dendritic cell recovery post-lymphodepletion: a potential mechanism for anti-cancer adoptive T cell therapy and vaccination.

Authors:  Mohamed Labib Salem; David J Cole
Journal:  Cancer Immunol Immunother       Date:  2009-11-18       Impact factor: 6.968

6.  Recovery from cyclophosphamide-induced lymphopenia results in expansion of immature dendritic cells which can mediate enhanced prime-boost vaccination antitumor responses in vivo when stimulated with the TLR3 agonist poly(I:C).

Authors:  Mohamed L Salem; C Marcela Díaz-Montero; Amir A Al-Khami; Sabry A El-Naggar; Osama Naga; Alberto J Montero; Ahmed Khafagy; David J Cole
Journal:  J Immunol       Date:  2009-02-15       Impact factor: 5.422

Review 7.  Harnessing the Microbiome to Enhance Cancer Immunotherapy.

Authors:  Michelle H Nelson; Marshall A Diven; Logan W Huff; Chrystal M Paulos
Journal:  J Immunol Res       Date:  2015-05-25       Impact factor: 4.818

Review 8.  Radiotherapy for non-small cell lung cancer in the immunotherapy era: the opportunity and challenge-a narrative review.

Authors:  Wu-Yan Xia; Wen Feng; Chen-Chen Zhang; Yu-Jia Shen; Qin Zhang; Wen Yu; Xu-Wei Cai; Xiao-Long Fu
Journal:  Transl Lung Cancer Res       Date:  2020-10

9.  Combination treatment with decitabine and ionizing radiation enhances tumor cells susceptibility of T cells.

Authors:  Cheol-Hun Son; Hong-Rae Lee; Eun-Kyoung Koh; Dong-Yeok Shin; Jae-Ho Bae; Kwangmo Yang; You-Soo Park
Journal:  Sci Rep       Date:  2016-09-27       Impact factor: 4.379

Review 10.  Leveraging Endogenous Dendritic Cells to Enhance the Therapeutic Efficacy of Adoptive T-Cell Therapy and Checkpoint Blockade.

Authors:  Mie Linder Hübbe; Ditte Elisabeth Jæhger; Thomas Lars Andresen; Mads Hald Andersen
Journal:  Front Immunol       Date:  2020-09-25       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.